Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Tabah, Ashley
Huggar, David
Kish, Jonathan
Bapat, Bela
Liassou, Djibril
Gajra, Ajeet
Miller, Talia
Copher, Ronda
Patel, Manali, I
机构：
[1] Bristol Myers Squibb, Summit, NJ USA
[2] Cardinal Hlth, Dublin, OH USA
[3] SUNY Upstate Med Univ, Syracuse, NY 13210 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21717
引用
收藏
页数：2
相关论文
共 50 条
  • [21] First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study
    Dechow, Tobias
    Riera-Knorrenschild, Jorge
    Hackanson, Bjoern
    Janssen, Jan
    Schulz, Holger
    Chiabudini, Marco
    Fischer von Weikersthal, Ludwig
    Budweiser, Stephan
    Nacke, Axel
    Taeuscher, Dagmar
    Welslau, Manfred
    Potthoff, Karin
    CANCER MEDICINE, 2021, 10 (22): : 8127 - 8137
  • [22] Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel
    Nishihara-Kato, Fuyumi
    Imai, Hisao
    Tsuda, Takeshi
    Wasamoto, Satoshi
    Nagai, Yoshiaki
    Kishikawa, Takayuki
    Miura, Yosuke
    Ono, Akihiro
    Yamada, Yutaka
    Masubuchi, Ken
    Osaki, Takashi
    Nakagawa, Junichi
    Umeda, Yukihiro
    Minemura, Hiroyuki
    Kozu, Yuki
    Taniguchi, Hirokazu
    Ohta, Hiromitsu
    Kaira, Kyoichi
    Kagamu, Hiroshi
    ONCOLOGY, 2024, 102 (01) : 30 - 42
  • [23] Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis
    Tan, Tianying
    Li, Shuangshuang
    Hu, Wenting
    Yue, Tinghui
    Zeng, Qi
    Zeng, Xingling
    Chen, Xiaochao
    Zhao, Xiangdong
    Xiao, Tianbao
    FRONTIERS IN MEDICINE, 2023, 10
  • [24] Phase II study of nab-paclitaxel plus carboplatin for patients with non-small-cell lung cancer and interstitial lung disease
    Kenmotsu, Hirotsugu
    Yoh, Kiyotaka
    Mori, Keita
    Ono, Akira
    Baba, Tomohisa
    Fujiwara, Yutaka
    Yamaguchi, Ou
    Ko, Ryo
    Okamoto, Hiroaki
    Yamamoto, Nobuyuki
    Ninomiya, Takashi
    Ogura, Takashi
    Kato, Terufumi
    CANCER SCIENCE, 2019, 110 (12) : 3738 - 3745
  • [25] Phase 3 study of carboplatin-paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer (NSCLC).
    Paz-Ares, Luis G.
    Luft, Alexander
    Tafreshi, Ali
    Gumus, Mahmut
    Mazieres, Julien
    Hermes, Barbara
    Senler, Filiz Cay
    Fulop, Andrea
    Rodriguez-Cid, Jeronimo
    Sugawara, Shunichi
    Cheng, Ying
    Novello, Silvia
    Halmos, Balazs
    Yue Shentu
    Kowalski, Dariusz
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer
    Kawano, Yuko
    Sasaki, Tomonari
    Yamaguchi, Hiroyuki
    Hirano, Katsuya
    Horiike, Atsushi
    Satouchi, Miyako
    Hosokawa, Shinobu
    Morinaga, Ryotaro
    Komiya, Kazutoshi
    Inoue, Koji
    Fujita, Yuka
    Toyozawa, Ryo
    Kimura, Tomoki
    Takahashi, Kosuke
    Nishikawa, Kazuo
    Kishimoto, Junji
    Nakanishi, Yoichi
    Okamoto, Isamu
    LUNG CANCER, 2018, 125 : 136 - 141
  • [27] First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study
    Dechow, Tobias
    Riera-Knorrenschild, Jorge
    Hackanson, Bjorn
    Janssen, Jan
    Schulz, Holger
    Oppermann, Ursula
    Chiabudini, Marco
    von Weikersthal, Ludwig Fischer
    Budweiser, Stephan
    Nacke, Axel
    Taeuscher, Dagmar
    Welslau, Manfred
    Potthoff, Karin
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (01) : 141 - 152
  • [28] Dose and schedule modifications of carboplatin plus nab-paclitaxel for elderly patients with squamous non-small cell lung cancer from the CAPITAL study
    Saito, G.
    Kogure, Y.
    Kada, A.
    Hashimoto, H.
    Atagi, S.
    Takiguchi, Y.
    Saka, H.
    Ebi, N.
    Inoue, A.
    Kurata, T.
    Yamanaka, T.
    Ando, M.
    Shibayama, T.
    Itani, H.
    Nishii, Y.
    Fujita, Y.
    Yamamoto, N.
    Gemma, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1020 - S1021
  • [29] Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer
    Kaira, Kyoichi
    Tomizawa, Yoshio
    Imai, Hisao
    Sakurai, Reiko
    Matsuura, Masana
    Yoshii, Akihiro
    Ochiai, Mai
    Kotake, Mie
    Ebara, Takeshi
    Saitoh, Jun-ichi
    Sunaga, Noriaki
    Minato, Koichi
    Saito, Ryusei
    Hisada, Takeshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 165 - 171
  • [30] Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer
    Kyoichi Kaira
    Yoshio Tomizawa
    Hisao Imai
    Reiko Sakurai
    Masana Matsuura
    Akihiro Yoshii
    Mai Ochiai
    Mie Kotake
    Takeshi Ebara
    Jun-ichi Saitoh
    Noriaki Sunaga
    Koichi Minato
    Ryusei Saito
    Takeshi Hisada
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 165 - 171
12345